TRVI
Trevi Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$17.26
+1.17%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 34.0K | — | — | — | — |
| Gross Profit | (34.0K) | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 41.4M | 33.5M | 39.4M | 23.7M | 19.8M |
| SG&A Expense | 18.2M | 15.8M | 12.1M | 10.2M | 10.1M |
| General & Admin Expense | 18.2M | 15.8M | 12.1M | 10.2M | 10.1M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 59.6M | 49.3M | 51.5M | 33.9M | 29.9M |
| Cost and Expenses | 59.6M | 49.3M | 51.5M | 33.9M | 29.9M |
| Operating Income (EBIT) | (59.6M) | (49.3M) | (51.5M) | (33.9M) | (29.9M) |
| Non-Operating | |||||
| Interest Income | 8.4M | 6.5M | 3.6M | 4.7M | 1.7M |
| Interest Expense | — | — | 4.0K | 391.0K | 780.0K |
| Net Interest Income | 8.4M | 6.5M | 3.6M | 4.4M | 960.0K |
| Other Non-Op Income/Expense | 8.4M | 6.5M | 3.6M | 4.8M | 719.0K |
| Non-Operating Income (excl Interest) | (8.4M) | (6.5M) | (3.6M) | (5.2M) | (1.9M) |
| EBT (Pre-Tax Income) | (51.2M) | (42.8M) | (47.9M) | (29.1M) | (29.2M) |
| Income Tax Expense | (70.0K) | (64.0K) | (30.0K) | (32.0K) | (36.0K) |
| Bottom Line | |||||
| Net Income | (51.1M) | (42.8M) | (47.9M) | (29.1M) | (29.2M) |
| Earnings from Cont. Ops | (51.1M) | (42.8M) | (47.9M) | (29.1M) | (29.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (51.1M) | (42.8M) | (47.9M) | (29.1M) | (29.2M) |
| Per Share | |||||
| Basic EPS | ($0.34) | ($0.29) | ($0.47) | ($0.29) | ($0.45) |
| Diluted EPS | ($0.34) | ($0.29) | ($0.47) | ($0.29) | ($0.45) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 156.6M | 145.1M | 101.0M | 99.0M | 64.5M |
| Diluted Shares Outstanding | 156.6M | 145.1M | 101.0M | 99.0M | 64.5M |
| Profitability Metrics | |||||
| EBITDA | (51.1M) | (42.7M) | (47.8M) | (28.6M) | (28.0M) |
| D&A | 103.0K | 144.0K | 147.0K | 123.0K | 43.0K |
| EBIT | (51.2M) | (42.8M) | (47.9M) | (28.7M) | (28.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026